An Empirical Examination of the Patented Medicine Prices Review Board Price Control Amendments on Drug Launches in Canada

Oliver Spicer and Paul Grootendorst

No 200003, Working Papers from Canadian Centre for Health Economics

Abstract: The Government of Canada plans to implement new controls on prices of patented drugs in January 2021. The literature indicates that such controls delay drug launches. The Government's unpublished analysis suggests that no delays will occur. To examine this claim, we use recent OECD country level data to estimate regression models of launch delays. These models suggest that thenew price controls will indeed delay access to new medicines in Canada.

Keywords: COVID-19; physical distancing; non-compliance fines; wage subsidies; risk of infection (search for similar items in EconPapers)
Pages: 23 pages
Date: 2020-07
References: View references in EconPapers View complete reference list from CitEc
Citations:

Published Online, July 2020

Downloads: (external link)
https://www.canadiancentreforhealtheconomics.ca/wp ... rootendorst-2020.pdf First version, 2020 (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:cch:wpaper:200003

Access Statistics for this paper

More papers in Working Papers from Canadian Centre for Health Economics Contact information at EDIRC.
Bibliographic data for series maintained by Adrian Rohit Dass ().